Kidney disease in HIV-infected patients

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 19, 2013, Pages 2660-2667

  Scarpino, M ^a   Pinzone, M R ^a   Di Rosa, M ^a   Madeddu, G ^b   Foca E ^c   Martellotta, F ^d   Schioppa, O ^d   Ceccarelli, G ^e   Celesia, B M ^a   D'Ettorre, G ^e   Vullo, V ^e   Berretta, S ^a   Cacopardo, B ^a   Nunnari, G ^a,f  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

ARF; CKD; HAART; HIV; HIVAN; Kidney

Indexed keywords

ABACAVIR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATAZANAVIR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIDANOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL EVALUATION; DRUG EFFECT; FANCONI RENOTUBULAR SYNDROME; GLOMERULUS FILTRATION RATE; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; NEPHROTOXICITY; RISK FACTOR; SCREENING; SIDE EFFECT;

AIDS-ASSOCIATED NEPHROPATHY; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS;

EID: 84886619862     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (118)

1. PALELLA FJ, BAKER RK, MOORMAN AC, CHMIEL JS, WOOD KC, BROOKS JT, HOLMBERG SD; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34. (Pubitemid 44306484)
2. DI BENEDETTO F, TARANTINO G, ERCOLANI G, BACCARANI U, MONTALTI R, DE RUVO N, BERRETTA M, ADANI GL, ZANELLO M, TAVIO M, CAUTERO N, TIRELLI U, PINNA AD, GERUNDA GE, GUARALDI G. Multicenter italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients. Oncologist 2013; 18: 592-599.
3. TAVIO M, GROSSI P, BACCARANI U, SCUDELLER L, PEA F, BERRETTA M, ADANI G, VIVARELLI M, RIVA A, TIRELLI U, BRESADOLA V, VIALE P, RISALITI A. HIV infected patients and liver transplantation: who, when and why. Curr HIV Res 2011; 9: 120-127.
4. SPINA M, CARBONE A, GLOGHINI A, SERRAINO D, BERRETTA M, TIRELLI U. Hodgkin's disease in patients with HIV infection. Adv Hematol 2011; 2011: pii: 402682.
5. SPINA M, CHIMIENTI E, MARTELLOTTA F, VACCHER E, BERRETTA M, ZANET E, LLESHI A, CANZONIERI V, BULIAN P, TIRELLI U. Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 2010; 116: 1495-1501.
6. MARTELLOTTA F, BERRETTA M, VACCHER E, SCHIOPPA O, ZANET E, TIRELLI U. AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies. Curr HIV Res 2009; 7: 634-638.
7. SIMONELLI C, TEDESCHI R, GLOGHINI A, TALAMINI R, BORTOLIN MT, BERRETTA M, SPINA M, MORASSUT S, VACCHER E, DE PAOLI P, CARBONE A, TIRELLI U. Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection. J Med Virol 2009; 81: 888-896.
8. BERRETTA M, ZANET E, DI BENEDETTO F, SIMONELLI C, BEARZ A, MORRA A, BONANNO S. BERRETTA S, TIRELLI U. Unusual presentation of metastatic hepatocellular carcinoma in an HIV/HCV coinfected patient: case report and review of the literature. Tumori 2008; 94: 589-591.
9. DI BENEDETTO F, DI SANDRO S, DE RUVO N, BERRETTA M, MONTALTI R, GUERRINI GP, BALLARIN R, DE BLASIIS MG, SPAGGIARI M, SMERIERI N, IEMMOLO RM, GUARALDI G, GERUNDA GE. Human Immunodeficiency virus and liver tranplantation: our point of view. Transplant Proc 2008; 40: 1965-1971.
10. DI BENEDETTO F, DI SANDRO S, DE RUVO N, BERRETTA M, MASETTI M, MONTALTI R, BALLARIN R, COCCHI S, POTENZA L, LUPPI M, GERUNDA GE. Kaposi's sarcoma after liver transplantation. J Cancer Res Clin Oncol 2008; 134: 653-658. (Pubitemid 351506416)
11. DI BENEDETTO F, DE RUVO N, BERRETTA M, MASETTI M, MONTALTI R, DI SANDRO S, BALLARIN R, CODELUPPI M, GUARALDI G, GERUNDA GE. Hepatocellular carcinoma in HIV patients treated by liver transplantation. Eur J Surg Oncol 2008; 34: 442-447.
12. BERRETTA M, MARTELLOTTA F, SIMONELLI C, DI BENEDETTO F, DE RUVO N, DRIGO A, BEARZ A, SPINA M, ZANET E, BERRETTA S, TIRELLI U. Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report. J Chemother 2007; 19: 343-346. (Pubitemid 47075133)
13. DI BENEDETTO F, DE RUVO N, BERRETTA M, MASETTI M, MONTALTI R, DI SANDRO S, QUINTINI C, CODELUPPI M, TIRELLI U, GERUNDA GE. Dont'deny liver transplantation to HIV patients with hepatocellular carcinoma in the highly active antiretroviral therapy era. J Clin Oncol 2006; 24: e26-27.
14. BERRETTA M, TIRELLI U. Colorectal cancer screening in HIV-infected patients 50 years of age and older: missed opportunities for prevention. Am J Gastroenterol 2006; 101: 907.
15. BERRETTA M, DI BENEDETTO F, SIMONELLI C, BEARZ A, BERRETTA S, MAUGERI D, TIRELLI U. Multidisciplinary approach in a HIV/HCV positive patient with liver metastases by colorectal cancer in the HAART era. Ann Oncol 2006; 17: 1333-1334. (Pubitemid 44288227)
16. NASTI G. MARTELLOTTA F, BERRETTA M, MENA M, FASAN M, DI PERRI G, TALAMINI R, PAGANO G, MONTRONI M, CINELLI R, VACCHER E, D'ARMINIO MONFORTE A, TIRELLI U; GICAT; ICONA. Impact of Highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 2003; 98: 2440-2446. (Pubitemid 37466659)
17. BERRETTA M, CINELLI R, MARTELLOTTA F, SPINA M, VACCHER E, TIRELLI U. Therapeutic approaches to AIDS-related malignancies. Oncogene 2003; 22: 6646-6659. (Pubitemid 37372345)
18. SPINA M, BERRETTA M, TIRELLI U. Hodgkin's disease in Hiv. Hematol Oncol Clin North Am 2003; 17: 843-858. (Pubitemid 36807600)
19. NUNNARI G, XU Y, ACHEAMPONG EA, FANG J, DANIEL R, ZHANG C, ZHANG H, MUKHTAR M, POMERANTZ RJ. Exogenous IL-7 induces Fas-mediated human neuronal apoptosis: potential effects during human im-munodeficiency virus type 1 infection. J Neurovirol 2005; 11: 319-328. (Pubitemid 41614511)
20. NUNNARI G, COCO C, PINZONE MR, PAVONE P, BERRETTA M, DI ROSA M, SCHNELL M, CALABRESE G, CACOPARDO B. The role of micronutrients in the diet of HIV-1-infected individuals. Front Biosci (Elite Ed) 2012; 4: 2442-2456.
21. ZANET E, BERRETTA M, DI BENEDETTO F, TALAMINI R, BALLARIN R, NUNNARI G, BERRETTA S, RIDOLFO A, LLESHI A, ZANGHÌ A, CAPPELLANI A, TIRELLI U. Pancreatic Cancer in HIV-positive patients: A clinical case-control study. Pancreas 2012; 41: 1331-1335.
22. BERRETTA M, GARLASSI E, CACOPARDO B, CAPPELLANI A, GUARALDI G, COCCHI S, DE PAOLI P, LLESHI A, IZZI I, TORRESIN A, DI GANGI P, PIETRANGELO A, FERRARI M, BEARZ A, BERRETTA S, NASTI G, DI BENEDETTO F, BALESTRERI L, TIRELLI U, VENTURA P. Hepatocellular carcinoma in HIV-infected patients: check early, Treat Hard. Oncologist 2011; 16: 1258-1269.
23. BERRETTA M, LLESHI A, CAPPELLANI A, BEARZ A, SPINA M, TALAMINI R, CACOPARDO B, NUNNARI G, MONTESARCHIO V, IZZI I, LANZAFAME M, NASTI G, BASILE F, BERRETTA S, FISICHELLA R, SCHIANTARELLI C, GARLASSI E, RIDOLFO A, GUELLA L, TIRELLI U. Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection. Curr HIV Res 2010; 8: 218-222.
24. BERRETTA M, CAPPELLANI A, DI BENEDETTO F, LLESHI A, TALAMINI R, CANZONIERI V, ZANET E, BEARZ A, NASTI G, LACCHIN T, BERRETTA S, FISICHELLA R, BALESTRERI L, TORRESIN A, IZZI I, ORTOLANI P, TIRELLI U. Clinical presentation and outcome of colorectal cancer in HIVpositive patients: a clinical case-control study. Onkologie 2009; 32: 319-324.
25. BERRETTA M, ZANET E, BASILE F, RIDOLFO AL, DI BENEDETTO F, BEARZ A, BERRETTA S, NASTI G, TIRELLI U. HIV-positive patients with liver metastases from colorectal cancer deserve the same therapeutic approach as the general population. Onkologie 2010; 33: 203-204.
26. ZANET E, BERRETTA M, MARTELLOTTA F, CACOPARDO B, FISICHELLA R, TAVIO M, BERRETTA S, TIRELLI U. Anal cancer: focus on HIV-positive patients in the HAART era. Curr HIV Res 2011; 9: 70-81.
27. NUNNARI G, XU Y, ACHEAMPONG EA, FANG J, DANIEL R, ZHANG C, ZHANG H, MUKHTAR M, POMERANTZ RJ. Exogenous IL-7 induces Fas-mediated human neuronal apoptosis: potential effects during human immunodeficiency virus type 1 infection. J Neurovirol 2005; 11: 319-328. (Pubitemid 41614511)
28. NUNNARI G, POMERANTZ RJ. IL-7 as a potential therapy for HIV-1-infected individuals. Expert Opin Biol Ther 2005; 5: 1421-1426. (Pubitemid 41579427)
29. NUNNARI G, BERRETTA M, PINZONE MR, DI ROSA M, CAPPELLANI A, BERRETTA S, TIRELLI U, MALAGUARNERA M, SCHNELL JM, CACOPARDO B. Hepatocellular carcinoma in HIV positive patients. Eur Rev Med Pharmacol Sci 2012; 16: 1257-1270.
30. MARTELLOTTA F, BERRETTA M, CACOPARDO B, FISICHELLA R, SCHIOPPA O, ZANGHÌ A, SPARTÀ D, CAPPELLANI A, TALAMINI R, IZZI I, RIDOLFO A, TORRESIN A, FIORICA F, TIRELLI U. Clinical presentation and outcome of squamous cell carcinoma of the anus in HIV-infected patients in the HAART-era: a GICAT experience. Eur Rev Med Pharmacol Sci 2012; 16: 1283-1291.
31. BERRETTA M, DI BENEDETTO F, DAL MASO L, CACOPARDO B, NASTI G, FACCHINI G, BEARZ A, SPINA M, GARLASSI E, DE RE V, FIORICA F, LLESHI A, TIRELLI U. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. Anticancer Drugs 2013; 24: 212-218.
32. DI ROSA M, MALAGUARNERA G, DE GREGORIO C, PALUMBO M, NUNNARI G, MALAGUARNERA L. Immuno-modulatory effects of vitamin D3 in human monocyte and macrophages. Cell Immunol 2012; 280: 36-43.
33. DI ROSA M, MALAGUARNERA L, NICOLOSI A, SANFILIPPO C, MAZZARINO C, PAVONE P, BERRETTA M, COSENTINO S, CACOPARDO B, PINZONE MR, NUNNARI G. Vitamin D3: an ever green molecule. Front Biosci (Schol Ed) 2013; 5: 247-260.
34. PINZONE MR, FIORICA F, DI ROSA M, MALAGUARNERA G, MALAGUARNERA L, CACOPARDO B, ZANGHÌ G, NUNNARI G. Non-AIDS-defining cancers among HIV-infected people. Eur Rev Med Pharmacol Sci 2012; 16: 1377-1388.
35. BEARZ A, VACCHER E, TALAMINI R, BERRETTA M, TIRELLI U. Comment on "Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection". Br J Cancer 2012; 106: 1899-1900.
36. NUNNARI G, SMITH JA, DANIEL R. HIV-1 Tat and AIDSassociated cancer: targeting the cellular anti-cancer barrier. J Exp Clin Cancer Res 2008; 27: 3.
37. PINZONE MR, CELESIA BM, DI ROSA M, CACOPARDO B, NUNNARI G. Microbial translocation in chronic liver diseases. Int J Microbiol 2012; 2012: 694629.
38. PINZONE MR, DI ROSA M, MALAGUARNERA M, MADEDDU G, FOCÀ E, CECCARELLI G, D'ETTORRE G, VULLO V, FISICHELLA R, CACOPARDO B, NUNNARI G. Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. Eur Rev Med Pharmacol Sci 2013; 17: 1218-1232.
39. PINZONE MR, DI ROSA M, CACOPARDO B, NUNNARI G. HIV RNA Suppression and immune restoration: can we do better? Clin Develop Immunol 2012; 515962.
40. NUNNARI G, OTERO M, DORNADULA G, VANELLA M, ZHANG H, FRANK I, POMERANTZ RJ. Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. AIDS 2002; 16: 39-45. (Pubitemid 34062180)
41. NUNNARI G, LETO D, SULLIVAN J, XU Y, MEHLMAN KE, KULKOSKY J, POMERANTZ RJ. Seminal reservoirs during an HIV type 1 eradication trial. AIDS Res Hum Retroviruses 2005; 21: 768-775. (Pubitemid 41434181)
42. NUNNARI G, SULLIVAN J, XU Y, NYIRJESY P, KULKOSKY J, CAVERT W, FRANK I, POMERANTZ RJ. HIV type 1 cervicovaginal reservoirs in the era of HAART. AIDS Res Hum Retroviruses 2005; 21: 714-718. (Pubitemid 41254237)
43. NUNNARI G, GUSSIO M, PINZONE MR, MARTELLOTTA F, COSENTINO S, CACOPARDO B, CELESIA BM. Cryptococcal meningitis in an HIV-1-infected person: relaps-es or IRIS? Case report and review of the literature. Eur Rev Med Pharmacol Sci 2013; 17: 1555-1559.
44. POMERANTZ RJ, NUNNARI G. HIV and GB virus C-can two viruses be better than one? N Engl J Med 2004; 350: 963-965. (Pubitemid 38269270)
45. DORNADULA G, NUNNARI G, VANELLA M, ROMAN J, BABINCHAK T, DE SIMONE J, STERN J, BRAFFMAN M, ZHANG H, POMERANTZ RJ. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. J Infect Dis 2001; 183: 1682-1687. (Pubitemid 32466709)
46. OTERO M, NUNNARI G, LETO D, SULLIVAN J, WANG FX, FRANK I, XU Y, PATEL C, DORNADULA G, KULKOSKY J, POMERANTZ RJ. Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART. AIDS Res Hum Retroviruses 2003; 19: 1097-1103. (Pubitemid 38037379)
47. NUNNARI G, ARGYRIS E, FANG J, MEHLMAN KE, POMERANTZ RJ, DANIEL R. Inhibition of HIV-1 replication by caffeine and caffeine-related methylxanthines. Virology 2005; 335: 177-184. (Pubitemid 40544907)
48. SMITH JA, NUNNARI G, PREUSS M, POMERANTZ RJ, DANIEL R. Pentoxifylline suppresses transduction by HIV-1-based vectors. Intervirology 2007; 50: 377-386. (Pubitemid 350014922)
49. PINZONE MR, CACOPARDO B, CONDORELLI F, DI ROSA M, NUNNARI G. Sirtuin-1 and HIV-1: An Overview. Curr Drug Targets 2013; 14: 648-652.
50. WANG FX, XU Y, SULLIVAN J, SOUDER E, ARGYRIS EG, ACHEAMPONG EA, FISHER J, SIERRA M, THOMSON MM, NAJERA R, FRANK I, KULKOSKY J, POMERANTZ RJ, NUNNARI G. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115: 128-137. (Pubitemid 40385513)
51. PINZONE MR, DI ROSA M, CELESIA BM, CONDORELLI F, MALAGUARNERA M, MADEDDU G, MARTELLOTTA F, CASTRONUOVO D, GUSSIO M, COCO C, PALERMO F, COSENTINO S, CACOPARDO B, NUNNARI G. LPS and HIV gp120 modulate monocyte/macrophage CYP27B1 and CYP24A1 expression leading to vitamin D consumption and hypovitaminosis D in HIV-infected individuals. Eur Rev Med Pharmacol Sci 2013; 17: 1938-1950.
52. CELESIA BM, CASTRONUOVO D, PINZONE MR, BELLISSIMO F, MUGHINI MT, LUPO G, SCARPINO MR, GUSSIO M, PALERMO F, COSENTINO S, CACOPARDO B, NUNNARI G. Late presentation of HIV infection: predictors of delayed diagnosis and survival in eastern Sicily. Eur Rev Med Pharmacol Sci 2013; 17: 2218-2224.
53. CASTRONUOVO D, CACOPARDO B, PINZONE MR, MORENO S, NUNNARI G. Bone disease in the setting of HIV infection. Eur Rev Med Pharmacol Sci 2013 [In press]
54. LA FERLA L, PINZONE MR, NUNNARI G, CACOPARDO B. Kaposi's sarcoma and HIV infection. Eur Rev Med Pharmacol Sci 2013;17: 2354-2365.
55. ADIH WK, SELIX RM, HU X. Trends in Diseases Reported on US Death Certificates that mentioned HIV infection, 1996-2006. J Int Assoc Physicians AIDS Care (Chic III) 2011; 10: 5-11.
56. SZCZECH LA, GANGE SJ, VAN DER HORST C, BARTLETT JA, YOUNG M, COHEN MH, ANASTOS K, KLASSEN PS, SVETKEY LP. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002; 61: 195-202. (Pubitemid 34075147)
57. GUPTA SK, MAMLIN BW, JOHNSON CS, DOLLINS MD, TOPF JM, DUBE MP. Prevalence of proteinuria and the development of chronic kidney disease in HIVinfected patients. Clin Nephrol 2004; 61: 1-6. (Pubitemid 38100837)
58. GARDNER LI, HOLMBERG SD, WILLIAMSON JM, SZCZECH LA, CARPENTER CC, ROMPALO AM, SCHUMAN P, KLEIN RS; HIV Epidemiology Research Study Group. Development of proteinuria or elevated serum creatinine and mortality in HIVinfected women. J Acquir Immune Defic Syndr 2003; 32: 203-209. (Pubitemid 36222723)
59. SZCZECH LA, HOOVER DR, FELDMAN JG, COHEN MH, GANGE SJ, GOOZÉ L, RUBIN NR, YOUNG MA, CAI X, SHI Q, GAO W, ANASTOS K. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004; 39: 1199-1206. (Pubitemid 40169320)
60. STEHMAN-BREEN CO, GILLEN D, STEFFES M, JACOBS DR JR, LEWIS CE, KIEFE CI, SISCOVICK D. Racial differences in early-onset renal disease among young adults: the coronary artery risk development in young adults (CARDIA) study. J Am Soc Nephrol 2003; 14: 2352-2357. (Pubitemid 37052383)
61. BERLINER AR, FINE DM, LUCAS GM, RAHMAN MH, RACUSEN LC, SCHEEL PJ, ATTA MG. Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol 2008; 28: 478-486. (Pubitemid 351501614)
62. UUSRDS: ANNUAL DATA REPORT. Bethesda, MD, National Institute of Health, NIDDK, 1997.
63. WINSTON JA, BURNS GC, KLOTMAN PE. The human immunodeficiency virus epidemic and HIV-associated nephropathy. Semin Nephrol 1998; 18: 373-377. (Pubitemid 28340461)
64. WINSTON JA, KLOTMAN ME, KLOTMAN PE. HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. Kidney Int 1999; 55: 1036-1040. (Pubitemid 29100716)
65. EUROPEAN AIDS CLINICAL SOCIETY. Guidelines: prevention and management of non-infectious comorbidities in HIV. Available at http: //www. europeanaidsclinicalsociety. org/images/stories/EACSPdf/EacsGuidelines-v6. 12edition.pdf. Accessed May 2013.
66. FRANCESCHINI N, NAPRAVNIK S, ERON J, SZCZECH LA, FINN WF. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005; 67: 1526-1531. (Pubitemid 40463131)
67. WYATT CM, ARONS RR, KLOTMAN PE, KLOTMAN ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006; 20: 561-565. (Pubitemid 43731600)
68. ROE J, CAMPBELL LJ, IBRAHIM F, HENDRY BM, POST FA. HIV care and the incidence of acute renal failure. Clin Infect Dis 2008; 47: 242-249. (Pubitemid 351920627)
69. CHOI AI, LI Y, DEEKS SG, GRUNFELD C, VOLBERDING PA, SHLIPAK MG. Association between kidney function and albuminuria with cardiovascular events in HIVinfected persons. Circulation 2010; 121: 651-658.
70. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39: S1-266.
71. STEVENS LA, CORESH J, GREENE T, LEVEY AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483. (Pubitemid 43855050)
72. O'RIORDAN SE, WEBB MC, STOWE JH, SIMPSON DE, KANDARPA M, COAKLEY AJ, NEWMAN DJ, Saunders JA, Lamb EJ. Cystatin C improves the detection of mild renal dysfunction in older patients. Ann Clin Biochem 2003; 40: 648-655. (Pubitemid 37421710)
73. COLL E, BOTEY A, ALVAREZ L, POCH E, QUINTÓ L, SAURINA A, VERA M, PIERA C, DARNELL A. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36: 29-34. (Pubitemid 30432560)
74. CHRISTENSSON AG, GRUBB A, NILSSON JA, NORRGREN K, STERNER G, SUNDKVIST G. Serum cystatin C advantageous compared with serum creatinine in the detection of mild but no severe diabetic nephropathy. J Intern Med 2004; 256: 510-518. (Pubitemid 39577585)
75. SHLIPAK MG, KATZ R, SARNAK MJ, FRIED LF, NEWMAN AB, STEHMAN-BREEN C, SELIGER SL, KESTENBAUM B, PSATY B, TRACY RP, SISCOVICK DS. Cystatin C and prognosis of cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237-246. (Pubitemid 46768607)
76. SHLIPAK MG, SARNAK MJ, KATZ R, FRIED LF, SELIGER SL, NEWMAN AB, SISCOVICK DS, STEHMAN-BREEN C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-2060. (Pubitemid 40664306)
77. LARSSON A, HELMERSSON J, HANSSON LO, BASU S. Increased serum cystatin C is associated with increased mortality in elderly men. Scand J Clin Lab Invest 2005; 65: 301-305. (Pubitemid 40910709)
78. LATERZA OF, PRICE CP, SCOTT MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002; 48: 699-707. (Pubitemid 34439101)
79. GRUBB A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 1992; 38(Suppl 1): S20-S27. (Pubitemid 23092541)
80. KNIGHT EL, VERHAVE JC, SPIEGELMAN D, HILLEGE HL, DE ZEEUW D, CURHAN GC, DE JONG PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-1421. (Pubitemid 38406982)
81. LANDRO L, DAMAS JK, FLO TH, HEGGELUND L, UELAND T, TJØNNFJORD GE, ESPEVIK T, AUKRUST P, FRØLAND SS. Decreased serum lipocalin-2 levels inhuman immunodeficiency virus-infected patients: increase during highly active anti-retroviral therapy. Clin Exp Immunol 2008; 152: 57-63. (Pubitemid 351347544)
82. RAVANI P, TRIPEPI G, MALBERTI F, TESTA S, MALLAMACI F, ZOCCALI C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449-2455. (Pubitemid 41725063)
83. FLISER D, KRONENBERG F, KIELSTEIN JT, MORATH C, BODEBÖGER SM, HALLER H, RITZ E. Asymmetric dimetholarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16: 2456-2461. (Pubitemid 41725064)
84. KALAYJIAN RC, FRANCESCHINI N, GUPTA SK, SZCZECH LA, MUPERE E, BOSCH RJ, SMURZYNSKI M, ALBERT JM. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008; 22: 481-487. (Pubitemid 351317289)
85. KRAWCZYK CS, HOLMBERG SD, MOORMAN AC, GARDNER LI, MCGWIN G JR, HIV Outpatient Study Group. Factors associated with renal failure in HIV-infected ambulatory patients. AIDS 2004; 18: 2171-2178. (Pubitemid 39463682)
86. BABUT-GAY ML, ECHARD M, KLEINKNECHT D, MEYRIER A. Zidovudine and nephropathy with human immunodeficiency virus infection. Ann Intern Med 1989; 111: 856-857. (Pubitemid 19283929)
87. IFUDU O, RAO TK, TAN CC, FLEISCHMAN H, CHIRGWIN K, FRIEDMAN EA. Zidovudine is beneficial in human immunodeficiency virus associated nephropathy. Am J Nephrol 1995; 15: 217-221.
88. KIRCHNER JT. Resolution of renal failure after initiation of HAART: three cases and a discussion of the literature. AIDS Read 2002; 12: 103-105, 110-112.
89. SZCZECH LA, EDWARDS LJ, SANDERS LL, VAN DER HORST C, BARTLETT JA, HEALD AE, SVETKEY LP. Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 2002; 57: 336-341. (Pubitemid 34477470)
90. STRATEGIES FOR MANAGEMENT OF ANTIRETROVIRAL THERAPY (SMART) STUDY GROUP. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
91. LONGENECKER CT, SCHERZER R, BACCHETTI P, LEWIS CE, GRUNFELD C, SHLIPAK MG. HIV viremia and changes in kidney function. AIDS 2009; 23: 1089-1096.
92. WINSTON JA, BRUGGEMAN LA, ROSS MD, JACOBSON J, ROSS L, D'AGATI VD, KLOTMAN PE, KLOTMAN ME. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001; 344: 1979-1984. (Pubitemid 32568152)
93. ATTA MG, GALLANT JE, RAHMAN MH, NAGAJOTHI N, RACUSEN LC, SCHEEL PJ, FINE DM. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006; 21: 2809-2813. (Pubitemid 44542235)
94. ROSS MJ, KLOTMAN PE, WINSTON JA. HIV-associated nephropathy: case study and review of the literature. AIDS Patient Care STDS 2000; 14: 637-645.
95. SZCZECH LA. Tackling the unknowns in HIV-related kidney diseases. N Engl J Med 2010; 363: 2058-2059.
96. CHOBANIAN AV, BAKRIS GL, BLACK HR, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572. (Pubitemid 37430158)
97. MOLITCH ME, DEFRONZO RA, FRANZ MJ, KEANE WF, MOGENSEN CE, PARVING HH, STEFFES MW; American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27(Suppl 1): S79-83.
98. BAKRIS GL, WILLIAMS M, DWORKIN L, ELLIOTT WJ, EPSTEIN M, TOTO R, TUTTLE K, DOUGLAS J, HSUEH W, SOWERS J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
99. JOSHI MK, LIU HH. Acute rhabdomyolysis and renal failure in HIV-infected patients: risk factors, presentation, and pathophysiology. AIDS Patient Care STDS 2000; 14: 541-548.
100. DORI L, BUONOMINI AR, VISCIONE M, SARMATI L, ANDREONI M. A case of rhabdomiolysis associated with raltegravir use. AIDS 2010; 24: 473-475.
101. ZEMBOWER TR, GERZENSHTEIN L, COLEMAN K, PALELLA FJ JR. Severe rhabdomyolysis associated with raltegravir use. AIDS 2008; 22: 1382-1384.
102. TASHIMA KT, HOROWITZ JD, ROSEN S. Indinavir nephropathy. N Engl J Med 1997; 336: 138-139.
103. DIELEMAN JP, STURKENBOOM MC, JAMBROES M, GYSSENS IC, WEVERLING GJ, TEN VEEN JH, SCHREY G, REISS P, STRICKER BH; ATHENA STUDY GROUP. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch Intern Med 2002; 162: 1493-1501. (Pubitemid 34747483)
104. CASADO JL, MORENO A, SABIDO R, MARTÍ-BELDA P, ANTELA A, DRONDA F, PEREZ-ELÍAS MJ, MORENO S. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response. HIV Clin Trials 2000; 1: 13-19.
105. BIRKUS G, HITCHCOCK MJM, CIHLAR T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46: 716-723. (Pubitemid 34157656)
106. MARTIN JL, BROWN CE, MATTHEWS-DAVIS N, REARDON JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994; 38: 2743-2749. (Pubitemid 24374430)
107. MAUSS S, BERGER F, SCHMUTZ G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19: 93-95. (Pubitemid 40111024)
108. LABARGA P, BARREIRO P, MARTIN-CARBONERO L, RODRIGUEZ-NOVOA S, SOLERA C, MEDRANO J, RIVAS P, ALBALATER M, BLANCO F, MORENO V, VISPO E, SORIANO V. Kidney tubular abnormalities in the absence if impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009; 23: 689-696.
109. GALLANT JE, PARISH MA, KERULY JC, MOORE RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40: 1194-1198. (Pubitemid 40490248)
110. MONTEAGUDO-CHU MO, CHANG MH, FUNG HB, BRÄU N. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients. J Pharm Pract 2012; 25: 552-559.
111. NELSON M, AZWA A, SOKWALA A, HARANIA RS, STEBBING J. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS 2008; 22: 1374-1376.
112. AHMAD M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med 2006; 52: 296-297. (Pubitemid 44862772)
113. D'YTHURBIDE G, GOUJARD C, MECHAI F, BLANC A, CHARPENTIER B, SNANOUDJ R. Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review. Nephrol Dial Transplant 2007; 22: 3656-3659. (Pubitemid 350212499)
114. COOPER RD, WIEBE N, SMITH N, KEISER P, NAICKER S, TONELLI M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51: 496-505.
115. NISHIJIMA T, SHIMBO T, KOMATSU H, TAKANO M, TANUMA J, TSUKADA K, TERUYA K, GATANAGA H, KIKUCHI Y, OKA S. Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study. J Infect Chemother 2013 [Epub ahead of print]
116. GALLANT JE, MOORE RD. Renal function with use of a tenofovir containing initial antiretroviral regimen. AIDS 2009; 24: 619-620.
117. PATEL KK, PATEL AK, RANJAN RR, PATEL AR, PATEL JK. Tenofovir-associated renal dysfunction in clinical practice: an observational cohort from Western India. Indian J Sex Transm Dis 2010; 31: 30-34.
118. RYOM L, MOCROFT A, KIRK O, WORM SW, KAMARA DA, REISS P, ROSS M, FUX CA, MORLAT P, MORANNE O, SMITH C, LUNDGREN JD; D:A:D Study Group. Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Study. J Infect Dis 2013; 207: 1359-1369.